EU's CHMP Warns About Boceprevir In HIV, Aliskiren In Diabetes, But Clears Orlistat And Reinstates Trasylol

The EU's scientific advisory panel, the CHMP, recommends prescribing information changes for drug/drug interactions with Merck's Victrelis and adverse events with Novartis' aliskiren, but clears obesity therapy orlistat of causing liver injury and reverses its 2007 negative opinion on Bayer's Trasylol.